SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

79

Enrollment

OTHER

Sponsor class

Conditions

CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Lymphomatoid Papulosis
Mycosis Fungoides
Skin Lymphoma
Cutaneous Lymphomas
Lymphoma
Hematologic Disorder

Interventions

DRUG: SGN-35

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]